GHRP-2 Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: Small early-phase pharmacodynamic studies on GH, cortisol and prolactin response.

Animal evidence: Preclinical ghrelin-receptor pharmacology.

Introduction & Mechanism of Action

Ghrelin-receptor agonist and growth-hormone secretagogue studied for GH-release research.

Hexapeptide ghrelin-receptor agonist; produces a strong GH pulse but with more pronounced cortisol, prolactin and appetite effects than the more selective Ipamorelin.

Receptors/targets: Ghrelin receptor (GHS-R1a)

Areas of Research Interest

• Growth-hormone release research
• Appetite-related studies

Benefits Reported in Research

• Growth-hormone release research
• Appetite-related studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 100–300 mcg

Reported frequency: 1× daily, subcutaneous

Reported cycle duration: 8–16 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on GHRP-2 reports administration at 100–300 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Increased appetite
• Flushing
• Water retention
• Injection-site reaction

Contraindications

• Active malignancy (theoretical concern)
• Pregnancy

Drug interactions

• Not well characterized in controlled human trials

Safety

• Cortisol and prolactin elevation more pronounced than with Ipamorelin
• Increased appetite may be undesirable depending on research goal

Ghrelin-receptor agonists as a class can affect appetite and cortisol; long-term human safety data is limited.

Expected Results & Comparison

GHRP-2 sits between Ipamorelin (more selective, milder side-effect profile) and GHRP-6 (strongest appetite-stimulating effect of the three) in the ghrelin-receptor-agonist family studied here — all three hit the same receptor but differ in how much they also elevate cortisol, prolactin and appetite.

References

Continue